BeOne Medicines (ONC) Competitors

BeOne Medicines (NASDAQ:ONC) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Which has stronger valuation & earnings, ONC or GSK?

GSK has higher revenue and earnings than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$3.81B	8.35	-$644.79M	-$3.72	-78.05
GSK	$40.10B	1.86	$3.29B	$1.94	18.81

Is ONC or GSK more profitable?

GSK has a net margin of 9.89% compared to BeOne Medicines' net margin of -9.40%. GSK's return on equity of 48.82% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	-9.40%	-7.55%	-4.42%
GSK	9.89%	48.82%	11.15%

Does the media favor ONC or GSK?

In the previous week, GSK had 13 more articles in the media than BeOne Medicines. MarketBeat recorded 28 mentions for GSK and 15 mentions for BeOne Medicines. GSK's average media sentiment score of 0.60 beat BeOne Medicines' score of 0.36 indicating that GSK is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	11 Very Positive mention(s)	6 Positive mention(s)	4 Neutral mention(s)	3 Negative mention(s)	4 Very Negative mention(s)	Positive

Do analysts rate ONC or GSK?

BeOne Medicines currently has a consensus price target of $327.56, suggesting a potential upside of 12.81%. GSK has a consensus price target of $37.38, suggesting a potential upside of 2.41%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
GSK	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11

Do institutionals and insiders hold more shares of ONC or GSK?

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 6.6% of BeOne Medicines shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more risk & volatility, ONC or GSK?

BeOne Medicines has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500.

Summary

GSK beats BeOne Medicines on 11 of the 16 factors compared between the two stocks.